Skip to content

Whittier Daily News

56°F
Monday, November 24th 2025

e-Edition

Trending:

Recent Quotes
My Watchlist
Indicators
Local Stocks
San Gabriel Valley
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Castle Biosciences, Inc. - Common stock (NQ:CSTL)

38.49 +0.61 (+1.61%)
Streaming Delayed Price Updated: 1:24 PM EST, Nov 24, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Castle Biosciences, Inc. - Common stock

< Previous 1 2 3 4 5 6 7 8 9
...
12 13 Next >
News headline image
New Data at ASTRO 2024 Shows Castle Biosciences’ DecisionDx®-SCC Test Provides More Precise Risk Stratification Than BWH Staging Alone to Guide Intensified Treatment for Immune Suppressed Patients with High-Risk Cutaneous Squamous Cell Carcinoma
From Castle Biosciences Inc.
Via Business Wire
News headline image
New Data at AFS 2024 Demonstrates the Strength of Castle Biosciences’ TissueCypher® Test in Independently Predicting Risk of Developing Esophageal Cancer, Guiding Risk-Aligned Management Decisions for Patients with Barrett’s Esophagus
From Castle Biosciences Inc.
Via Business Wire
News headline image
Sotera Health Stock Earns 91 RS Rating ↗
On Tuesday, Sotera Health stock hit a key technical milestone, with its Relative Strength Rating climbing to 91, up from 86 the day before. 
Via Investor's Business Daily
News headline image
Castle Biosciences’ Chief Operating Officer Kristen Oelschlager Named Arizona Bioscience Leader of the Year
From Castle Biosciences Inc.
Via Business Wire
News headline image
DecisionDx®-Melanoma Can Identify Melanoma Patients with Low Risk of Sentinel Lymph Node Positivity Who May Safely Forego Biopsy Surgery, New Independent Study Affirms
From Castle Biosciences Inc.
Via Business Wire
News headline image
Study Confirms the Ability of Castle Biosciences' DecisionDx®-SCC Test to Predict Likelihood of Benefit from Adjuvant Radiation Therapy in Patients with High-Risk Cutaneous Squamous Cell Carcinoma
From Castle Biosciences Inc.
Via Business Wire
News headline image
Castle Biosciences to Participate in Upcoming Investor Conferences
From Castle Biosciences Inc.
Via Business Wire
News headline image
Yum China Posts Upbeat Earnings, Joins Clear Secure, TG Therapeutics, Bioventus And Other Big Stocks Moving Higher On Tuesday ↗
 
Via Benzinga
News headline image
CSTL Stock Earnings: Castle Biosciences Beats EPS, Beats Revenue for Q2 2024 ↗
CSTL stock results show that Castle Biosciences beat analyst estimates for earnings per share and beat on revenue for the second quarter of 2024. 
Via InvestorPlace
News headline image
Castle Biosciences Reports Second Quarter 2024 Results
From Castle Biosciences Inc.
Via Business Wire
News headline image
Castle Biosciences to Present at the Canaccord Genuity 44th Annual Growth Conference
From Castle Biosciences Inc.
Via Business Wire
News headline image
ON Semiconductor Posts Upbeat Earnings, Joins Oil States International, CommScope Holding And Other Big Stocks Moving Higher On Monday ↗
 
Via Benzinga
News headline image
Castle Biosciences and Skin Cancer Survivor Teddi Mellencamp Arroyave Launch Campaign to Increase Awareness of Melanoma
From Castle Biosciences Inc.
Via Business Wire
News headline image
Castle Biosciences to Release Second Quarter 2024 Financial Results and Host Conference Call on Monday, Aug. 5, 2024
From Castle Biosciences Inc.
Via Business Wire
News headline image
Castle Biosciences Honored with Top Workplaces Awards
From Castle Biosciences Inc.
Via Business Wire
News headline image
Top 5 Health Care Stocks That May Explode In July ↗
 
Via Benzinga
News headline image
Why NIO Shares Are Trading Lower By Over 8%? Here Are Other Stocks Moving In Friday's Mid-Day Session ↗
Shares of NIO Inc. (NYSE:NIO) fell sharply during Friday's session after the company disclosed that Steven Wei Feng has resigned as the Chief Financial Officer for personal and family 
Via Benzinga
News headline image
Recent AGA Clinical Practice Guideline Acknowledges That Individuals Who May Be at Increased Risk of Progression to Esophageal Cancer Might Be Identified Using Tissue-Based Biomarkers, Particularly Castle Biosciences’ TissueCypher® Test
From Castle Biosciences Inc.
Via Business Wire
News headline image
Castle Biosciences Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From Castle Biosciences Inc.
Via Business Wire
News headline image
12 Health Care Stocks Moving In Wednesday's After-Market Session ↗
 
Via Benzinga
News headline image
Castle Biosciences’ Founder, President and CEO Derek Maetzold Named an EY Entrepreneur Of The Year® 2024 Gulf South Award Winner
From Castle Biosciences Inc.
Via Business Wire
News headline image
Castle Biosciences to Present New Data at 2024 ASCO® Annual Meeting Highlighting Use of DecisionDx®-Melanoma to Identify Early-Stage Melanoma Patients at High Risk of Metastasis to the Central Nervous System to Prompt Use of Imaging Surveillance
From Castle Biosciences Inc.
Via Business Wire
News headline image
New Publication Shows DecisionDx®-SCC Identifies High-Risk Squamous Cell Carcinoma Patients Who Are Likely to Benefit from Adjuvant Radiation Therapy and Those Who Can Consider Deferring Treatment Based on Biological Risk of Metastasis
From Castle Biosciences Inc.
Via Business Wire
News headline image
Castle Biosciences to Present at the Leerink Partners Healthcare Crossroads Conference
From Castle Biosciences Inc.
Via Business Wire
News headline image
Castle Biosciences Expands Evidence Supporting the Performance of its TissueCypher® Barrett’s Esophagus Test in Predicting Future Development of Esophageal Cancer Through Multiple Data Presentations at DDW 2024
From Castle Biosciences Inc.
Via Business Wire
News headline image
Castle Biosciences’ IDgenetix® Test Receives 2024 MedTech Breakthrough Award for “Best Overall Mental Health Solution”
From Castle Biosciences Inc.
Via Business Wire
News headline image
Largest Prospective Study to Date Further Supports Performance of DecisionDx®-UM for Metastatic Risk Stratification in Uveal Melanoma and Utility of PRAME Biomarker for Refining Risk When Considered with DecisionDx-UM Class Result
From Castle Biosciences Inc.
Via Business Wire
News headline image
DecisionDx®-SCC Significantly Improves Prediction Accuracy of Metastatic Events after Mohs Surgery in New Study of Patients with High-Risk Cutaneous Squamous Cell Carcinoma Tumors of the Head and Neck
From Castle Biosciences Inc.
Via Business Wire
News headline image
CSTL Stock Earnings: Castle Biosciences Beats EPS, Beats Revenue for Q1 2024 ↗
CSTL stock results show that Castle Biosciences beat analyst estimates for earnings per share and beat on revenue for the first quarter of 2024. 
Via InvestorPlace
News headline image
Castle Biosciences Reports First Quarter 2024 Results
From Castle Biosciences Inc.
Via Business Wire
< Previous 1 2 3 4 5 6 7 8 9
...
12 13 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.